Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
AACR, ABR, absorption, accredited, ADC, adequate, adhere, adherence, adipose, adrenal, AdventHealth, advisory, Agency, aggressive, agreed, agriculture, AI, al, anabolic, anorexia, antibody, anticancer, antiemetic, antigen, application, Arieli, arm, artificial, ASGE, ASH, assume, Assuta, attached, Attorney, augment, Australia, Barad, basal, baseline, basic, Benjamin, big, biggest, bioavailability, Biomedical, biotechnology, BMT, Bone, Boston, Boulder, Brigham, CA, cachexia, CAGR, California, caloric, calorie, Canada, Cao, career, Caroline, catabolism, CEO, certified, Cesamet, CFO, Chair, chemist, Chicago, cholangiopancreatography, circulating, cognitive, College, Colorado, committed, complication, compound, computational, construction, convenient, Council, counsel, couple, covalently, CSC, CTC, cum, daily, Dana, Dean, dearth, death, Dekel, department, deposition, Deputy, derived, Dermatology, device, difficult, diminished, direction, disorientation, display, Dissection, dosage, Dronabinol, duration, Dynamic, EADO, EADV, earned, Economy, efficient, EHA, elevated, ELN, EMEA, emulsion, endoscopic, endoscopy, Engineering, England, enriched, EORTC, era, ERCP, Erez, Eshdat, ESMO, European, EUS, exceed, exhibiting, expand, export, extensive, extensively, extracellular, Eyal, factor, Faculty, failure, fat, fatigue, fellowship, firm, firstly, Florida, fluid, food, forecast, fragility, France, Free, French, ft, Fu, Gastro, gemtuzumab, gene, GI, goal, gradual, graduating, great, greater, greatly, Gsap, guidance, Gustave, Haifa, Halpern, Han, Harvard, head, Hemato, Hematology, Hochman, Hospital, HPMC, hydroxypropylmethylcellulose, IARC, ideally, Ilan, Illinoi, Immunology, impairment, Importantly, incidence, inconclusive, ingestion, inoculated, INSERM, insufficiency, insulin, intake, Intelligence, invitro, involuntary, Japan, Kingdom, laude, leadership, lean, led, Leukemia, level, Li, limit, limited, linker, Lior, lipid, Liver, Los, Marinol, Marrow, Master, MD, medroxyprogesterone, megestrol, metabolic, mg, MHA, mice, Ministry, missile, MIT, mixed, MOH, monoclonal, mood, morbidity, multicenter, multidisciplinary, multifactorial, muscle, mutiny, Mylotarg, myopathy, nabilone, navigation, Nephrology, Noam, North, NTT, Nutrition, nutritional, objective, OLED, onset, OSD, ozogamicin, Parenteral, parsing, partnership, passionate, PDA, peak, Pediatric, peer, persistently, pervasive, PhD, physician, pilot, polymer, poor, poorly, population, Portnoy, postdoctoral, potency, predominantly, preforming, preliminary, prescription, president, prevalence, primary, Prof, Professor, proficient, profile, protein, psychological, published, pure, purposing, qualified, Questionnaire, Radiology, Rambam, rapid, rare, Recannati, reduction, Regenerative, region, relief, reside, Resignation, retrograde, Robert, robotic, Roussy, Sackler, Sarcoma, Sativex, Sativusin, Scapa, school, science, scientist, senior, SFD, shaulfied, Sheba, shift, Shomron, Shor, Sig, Sigal, Sigalit, skeletal, skin, sleep, small, social, solid, solution, Sourasky, spearheaded, specialist, sq, startup, starvation, steady, stem, steroidal, Submucosal, successfully, Sun, superior, suspended, sustained, Symptom, symptomatic, synergism, tageza, Taro, Tavor, Technion, Teva, Ther, threat, thromboembolism, TIC, Tokyo, Toren, traditional, training, Transduct, Transfusion, Transplantation, tthe, typically, ultimately, ultrasound, understanding, understood, unformulated, unicenter, Union, university, unresponsive, USD, vast, Venereology, versatile, Vice, visit, vol, VP, wasting, weekly, weighed, Weizmann, wellbeing, withdrew, Women, Zamir, Ziv
Removed:
aggregate, fixed, full, March
Filing tables
Filing exhibits
CNBX similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION OF
PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of CNBX PHARMACEUTICALS INC. (the “Company”) on Form 10-Q for the period ended November 30, 2022, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Uri Ben Or, Chief Financial Officer (Principal Financial Officer) of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, that, to my knowledge:
1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: January 13, 2023 | By: | /s/ Uri Ben Or | |
Uri Ben Or | |||
Chief Financial Officer (Principal Financial Officer) | |||